Literature DB >> 18825386

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Stefano Cirillo1, Massimo Petracchini, Lorenza Scotti, Teresa Gallo, Annalisa Macera, Maria Cristina Bona, Cinzia Ortega, Pietro Gabriele, Daniele Regge.   

Abstract

To evaluate diagnostic performance of endorectal magnetic resonance (eMR) for diagnosing local recurrence of prostate cancer (PC) in patients with previous radical prostatectomy (RP) and to assess whether contrast-enhanced (CE)-eMR improved diagnostic accuracy in comparison to unenhanced study. Unenhanced eMR data of 72 male patients (mean of total PSA: 1.23 +/- 1.3 ng/ml) with previous RP were interpreted retrospectively and classified either as normal or suspicious for local recurrence. All eMR examinations were re-evaluated also on CE-eMR 4 months after the first reading. Images were acquired on a 1.5-T system. These data were compared to the standard of reference for local recurrence: prostatectomy bed biopsy results; choline positron emission tomography results; PSA reduction or increase after pelvic radiotherapy; PSA modification during active surveillance. Sensitivity, specificity, predictive positive value, negative predictive value and accuracy were 61.4%, 82.1%, 84.4%, 57.5% and 69.4% for unenhanced eMR and 84.1%, 89.3%, 92.5%, 78.1% and 86.1% for CE-eMR. A statistically significant difference was found between accuracy and sensitivity of the two evaluations (chi(2) = 5.33; p = 0.02 and chi(2) = 9.00; p = 0.0027). EMR had great accuracy for visualizing local recurrence of PC after RP. CE-eMR improved diagnostic performance in comparison with T2-weighted imaging alone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18825386     DOI: 10.1007/s00330-008-1174-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  42 in total

1.  11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.

Authors:  Soichiro Yoshida; Kazuaki Nakagomi; Shuichi Goto; Masami Futatsubashi; Tatsuo Torizuka
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

2.  The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy.

Authors:  Stephen J Freedland; Leslie A Mangold; Patrick C Walsh; Alan W Partin
Journal:  J Urol       Date:  2005-10       Impact factor: 7.450

Review 3.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

Authors:  T J Polascik; J E Oesterling; A W Partin
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

4.  Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Authors:  Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

5.  Value of transrectal ultrasound in identifying local disease after radical prostatectomy.

Authors:  D A Kapoor; N F Wasserman; G Zhang; P K Reddy
Journal:  Urology       Date:  1993-06       Impact factor: 2.649

6.  Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Authors:  Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

7.  Detection of local recurrence after radical prostatectomy by prostate specific antigen and transrectal ultrasound.

Authors:  A S Abi-Aad; M T Macfarlane; A Stein; J B deKernion
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

8.  Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease.

Authors:  J W Walsh; M A Amendola; K F Konerding; J Tisnado; T A Hazra
Journal:  Radiology       Date:  1980-10       Impact factor: 11.105

Review 9.  Epidemiology of prostate cancer.

Authors:  E David Crawford
Journal:  Urology       Date:  2003-12-22       Impact factor: 2.649

10.  Changes in prostate cancer incidence and treatment in USA.

Authors:  G L Lu-Yao; E R Greenberg
Journal:  Lancet       Date:  1994-01-29       Impact factor: 79.321

View more
  55 in total

Review 1.  Dynamic contrast-enhanced magnetic resonance imaging and pharmacokinetic models in prostate cancer.

Authors:  Tobias Franiel; Bernd Hamm; Hedvig Hricak
Journal:  Eur Radiol       Date:  2010-12-24       Impact factor: 5.315

Review 2.  PET/MR in prostate cancer: technical aspects and potential diagnostic value.

Authors:  Michael Souvatzoglou; Matthias Eiber; Axel Martinez-Moeller; Sebastian Fürst; Konstantin Holzapfel; Tobias Maurer; Sibylle Ziegler; Stephan Nekolla; Markus Schwaiger; Ambros J Beer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-24       Impact factor: 9.236

3.  The value of multimodality imaging in the investigation of a PSA recurrence after radical prostatectomy in the Irish hospital setting.

Authors:  L C McLoughlin; S Inder; D Moran; C O'Rourke; R P Manecksha; T H Lynch
Journal:  Ir J Med Sci       Date:  2017-06-13       Impact factor: 1.568

4.  Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?

Authors:  Sotirios Chondrogiannis; Maria Cristina Marzola; Alice Ferretti; Gaia Grassetto; Anna Margherita Maffione; Lucia Rampin; Stefano Fanti; Francesco Giammarile; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-25       Impact factor: 9.236

Review 5.  Multiparametric MRI in prostate cancer management.

Authors:  Linda M Johnson; Baris Turkbey; William D Figg; Peter L Choyke
Journal:  Nat Rev Clin Oncol       Date:  2014-05-20       Impact factor: 66.675

6.  Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition.

Authors:  Andrew B Rosenkrantz; Anunita Khasgiwala; Ankur M Doshi; Justin M Ream; Samir S Taneja; Herbert Lepor
Journal:  Abdom Radiol (NY)       Date:  2017-01

7.  [Prostate cancer].

Authors:  T Franiel; N Eckardt; M Waginger; M Horstmann
Journal:  Radiologe       Date:  2014-05       Impact factor: 0.635

8.  Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy.

Authors:  Berrend G Muller; Aradhana Kaushal; Sandeep Sankineni; Elena Lita; Anthony N Hoang; Arvin K George; Soroush Rais-Bahrami; Jochen Kruecker; Pingkun Yan; Sheng Xu; Jean J de la Rosette; Maria J Merino; Bradford J Wood; Peter A Pinto; Peter L Choyke; Baris Turkbey
Journal:  Urol Oncol       Date:  2015-08-08       Impact factor: 3.498

Review 9.  Imaging techniques for prostate cancer: implications for focal therapy.

Authors:  Baris Turkbey; Peter A Pinto; Peter L Choyke
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

10.  Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?

Authors:  Hebert Alberto Vargas; Alexandre G Martin-Malburet; Toshikazu Takeda; Renato B Corradi; James Eastham; Andreas Wibmer; Evis Sala; Michael J Zelefsky; Wolfgang A Weber; Hedvig Hricak
Journal:  Urol Oncol       Date:  2016-06-23       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.